JPMorgan Chase & Co. Buys 140,779 Shares of Soleno Therapeutics, Inc. $SLNO

JPMorgan Chase & Co. grew its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 52.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 407,444 shares of the company’s stock after acquiring an additional 140,779 shares during the period. JPMorgan Chase & Co. owned 0.77% of Soleno Therapeutics worth $27,543,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC increased its holdings in Soleno Therapeutics by 255.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 280,984 shares of the company’s stock worth $18,995,000 after purchasing an additional 201,983 shares during the period. Castleark Management LLC bought a new position in shares of Soleno Therapeutics during the 2nd quarter worth $2,919,000. TimesSquare Capital Management LLC grew its position in shares of Soleno Therapeutics by 52.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 377,566 shares of the company’s stock worth $25,523,000 after buying an additional 130,197 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Soleno Therapeutics during the third quarter valued at $1,000,000. Finally, Marshall Wace LLP raised its holdings in shares of Soleno Therapeutics by 133.0% in the second quarter. Marshall Wace LLP now owns 288,334 shares of the company’s stock valued at $24,157,000 after acquiring an additional 164,580 shares in the last quarter. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Stock Up 2.6%

Soleno Therapeutics stock opened at $39.07 on Friday. Soleno Therapeutics, Inc. has a 1-year low of $32.63 and a 1-year high of $90.32. The business has a fifty day moving average price of $42.63 and a 200-day moving average price of $53.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of 169.88 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. Equities research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Analyst Ratings Changes

SLNO has been the topic of several recent research reports. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective (up from $110.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. Zacks Research downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Wall Street Zen lowered Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Wells Fargo & Company cut their price target on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.38.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.